Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, PF-06801591(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13334MR)

This product GTTS-WQ13334MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, PF-06801591(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ13334MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13151MR IVTScrip™ mRNA-Anti-NGF, PF-04383119(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA PF-04383119
GTTS-WQ14758MR IVTScrip™ mRNA-Anti-TNFRSF8, SGN-35(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA SGN-35
GTTS-WQ14467MR IVTScrip™ mRNA-Anti-MAPT, RO-7105705(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA RO-7105705
GTTS-WQ4723MR IVTScrip™ mRNA-Anti-IL21, BOS161721(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BOS161721
GTTS-WQ6498MR IVTScrip™ mRNA-Anti-CD274, CX-072(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CX-072
GTTS-WQ6455MR IVTScrip™ mRNA-Anti-HA, CT-P23(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CT-P23
GTTS-WQ562MR IVTScrip™ mRNA-Anti-ERBB2, 4D5-8(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA 4D5-8
GTTS-WQ11776MR IVTScrip™ mRNA-Anti-IL23A, MK-3222(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MK-3222
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW